Sarepta Therapeutics (SRPT) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to the Sarepta Therapeutics First Quarter twenty twenty five Financial Results Conference Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Mary Jenkins, Associate Director, Investor Relations. Please go ahead. Speaker1 Thank you, Marvin, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the firs ...

据招股书披露，瑞博生物成立于2007年，是研究和开发小核酸药物、尤其专注于siRNA疗法的全球领军 者，也是最早涉足该领域的开拓者之一。公司致力于率先开发创新疗法，以彻底改变亟需解决的疾病治 疗方式，这些疾病包括心血管、代谢类、肾脏和肝脏疾病。 瑞博生物在招股书中称，公司已建立自主研发的技术平台，涵盖小核酸药物开发的所有关键方面，从药 物递送、化学修饰、多靶点药物设计到模型引导的药物开发和生产，实现从早期研究到商业化的全生命 周期支持。这种整合和可扩展的方法已通过瑞博生物的小核酸候选药物管线进行验证，并继续推动企业 药物开发过程的创新和效率。 21世纪经济报道记者 唐唯珂 广州报道 4月25日，苏州瑞博生物技术股份有限公司（以下简称"瑞博生物"）正式向港交所递交主板上市申请， 联席保荐人为中金公司与花旗银行。 这是继2021年科创板终止审核后，这家中国小核酸药物企业的又一重大资本动作。公司曾于2020年12月 29日申报科创板并获受理，在经过一轮问询与回复后撤回申报材料，2021年5月21日被上交所终止。 凭借全球领先的siRNA（小干扰RNA）技术平台及丰富的临床管线，瑞博生物在小核酸药物领域积累了 深厚的 ...

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company announced podium presentations for its lead INTASYL product candidates, PH-762 and PH-894, at the 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany [1] Product Candidates - PH-762 is an INTASYL siRNA compound targeting PD-1, currently undergoing evaluation in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, showing promising preclinical efficacy and favorable tolerability [2][4] - PH-894 selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, representing a novel approach to improve adoptive cell therapy [3] Conference Presentations - Melissa Maxwell, Phio's Director of Research and Program Management, will present on PH-762 during the Plenary Session 3, focusing on its preclinical advances and ongoing clinical evaluation [2] - PH-894 will be discussed in Plenary Session 11, highlighting its potential to increase NK cell activity for adoptive cell therapy [3]

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsson - Chief Scientific Officer Kyle Moran - Chief Financial Officer Conference Call Participants Ron Feiner - JPMorgan Salim Syed - Mizuho Joon Lee - Truist Securities Joe Schwartz - Leerink Partners Roger Song - Jefferies Catherine Novack - Jones Trading Ryan Deschner - Raymond James Madison El-Saadi - B. Riley O ...

Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today. My name is Gem Hopkins, Vice President of Investor Relations and Corporate Communications at Silence. Joining me on today’s call are Craig Tooman, our President and CEO, who will provide an update on the business; Rhonda Hellums, our Chief Financial Officer, who will review our financial performance; and Steven Romano, our Chief R&D Officer, who will provide a clinical update. For those of you participating via conference ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securi ...